论文部分内容阅读
吡哆辛(Pyridoxine)在体内转化为磷酸吡哆醛,后者为氨基转移、某些氨基酸脫羧和半胱氨酸脫硫所需的辅酶。吡哆辛与脂肪代谢亦有密切关系:动物缺乏时产生动脉粥样化病变;每日给动脉粥样化患者肌注50毫克,可使血胆固醇浓度降低。吡哆辛给大白鼠口饲或皮下注射1克/公斤无显著不良反应,3—4克/公斤时方引起惊厥。半数致死量(LD_(50))口饲时为6克/公斤,皮下注射为3.7克/公斤,靜注为667.5±18.3毫克/公斤。本文研究吡哆辛对实验性心律失常的防治效能。
Pyridoxine is converted to pyridoxal phosphate in vivo, the latter being a coenzyme required for amino transfer, some amino acid decarboxylation, and cysteine desulfurization. There is also a close relationship between pyridoxine and fat metabolism: atherosclerosis occurs when animals are deficient; intramuscular injection of 50 mg daily to patients with atherosclerosis results in a reduction in blood cholesterol levels. Pyrazoxine given to mice 1 g / kg oral or subcutaneous injection had no significant adverse reactions, 3-4 g / kg when induced convulsion. The median lethal dose (LD_ (50)) was 6 g / kg for oral administration, 3.7 g / kg for subcutaneous injection, and 667.5 ± 18.3 mg / kg for intravenous injection. This article studies the efficacy of pyridoxine in the prevention and treatment of experimental arrhythmia.